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Abstract
Background: Molecular analyses of the c-kit and PDGFRα genes have contributed greatly to our
understanding of the development of gastrointestinal stromal tumors (GISTs), but little is known
about their malignant potential. The aim of our study was to evaluate cell cycle regulators as
potential prognostic markers in GISTs.
Methods: We investigated 104 KIT positive GISTs from various tumor sites in immunoassays on
CD34, Ki67 and particularly on P53, BCL-2 and Cyclin D1. The results were compared with tumor
size, mitotic rate, proliferative activity, histological subtype, nuclear atypia and risk assessment
according to Fletcher and Miettinen. Occurrence of metastases and survival were also taken into
account.
Results:  The expression of P53 was significantly correlated with high risk criteria towards
malignancy and epithelioid differentiation in GISTs. Likewise P53 label correlated significantly with
the established prognostic indicators: tumor size, mitotic rate, nuclear atypia and proliferative
activity. Regarding the site of tumor presentation, P53 was not a decisive factor. BCL-2 and Cyclin
D1 expression was not related to any of the prognostic indicators.
Conclusion: The present data identified P53 being a recommendable marker for predicting the
risk of malignancy in GISTs. In addition, we found P53 significantly correlated with epithelioid tumor
differentiation, independent of tumor site. BCL-2 and Cyclin D1, however, did not prove to be
deciding markers for diagnosis and prognosis.
Background
In recent years, progress has been achieved in establishing
accurate diagnoses of gastrointestinal stromal tumors
(GISTs), elucidating their molecular pathogenesis and
developing a specific treatment. GISTs are defined as mes-
enchymal tumors of stomach and intestine that express
KIT (CD117) and show either a c-kit mutation or a muta-
tion in the gene that encodes the platelet-derived growth
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factor receptor alpha (PDGFRα) [1-3]. Mutations in both
genes lead to ligand independent dimerization of trans-
membrane tyrosine kinase receptor type III and to intrac-
ytoplasmic signal transduction via phosphorylation of
tyrosine kinase [4-7]. The tyrosine kinase receptor inhibi-
tor imatinib (Glivec ®) has proven to be highly successful
for the treatment of metastasized GISTs. Currently, (neo-)
adjuvant imatinib therapy is being tested in order to min-
imize the risk of metastasis. The histological appearance
of GISTs is variable, but in general there are two patterns:
epithelioid and spindle cell [8,9]. Epithelioid GISTs have
been described with a variable nest-like, trabecular and
pleomorphic differentiation [9].
Tumor size and mitotic rate are proven criteria for predict-
ing the risk of malignancy [10,11]. Tumor localization
and histological differentiation correlate with prognosis,
too [11-14]. GISTs in general have a high malignant
potential, because up to 50% of patients suffer from
metastases already at the time of primary diagnosis [9].
Criteria that predict malignant potential could help clini-
cians to treat only patients who need therapy. Such criteria
should minimize side effects and costs for cases of low
metastatic risk [12,13]. However, there is little informa-
tion about the malignant development of GISTs. That risk
may increase with the number of acquired genetic altera-
tions in regulator genes, such as cellular oncogenes or sup-
pressor genes [15].
The tumor suppressor P53 and the antiapoptotic protein
BCL-2 attract particular attention, because they are
involved in DNA repair and cell death. Functional loss of
P53 promotes transformation, whereas BCL-2 blocks
apoptosis and enhances proliferation. Several studies
have addressed the impact of P53 on GIST prognosis
using varying cut off levels from 1% to 50% [16-20]. BCL-
2 expression has been extensively investigated in gastroin-
testinal mesenchymal tumors including GISTs, but results
were heterogeneous [17,19,21-23].
Cyclin D1 promotes G1/S transition [24,25] by regulating
the activity of the Cyclin-dependent protein kinases CDK4
and CDK6, and interferes with cell survival and division
[26]. Cyclin D1 overexpression has been found impli-
cated in several types of human neoplasias [27]. Reduced
expression of Cyclin D1 and poorer outcome has been
detected in breast carcinomas [28]. and in a few GISTs
[29]. Others reported significant correlation between Cyc-
lin D1 expression and outcome or histological pattern
[20,30].
The aim of the present study was to evaluate cell cycle reg-
ulators as potential prognostic markers in GISTs. Beside
KIT, CD34 and Ki67 antigen, we investigated the expres-
sion of P53, BCL-2, and Cyclin D1. The data from GISTs
of the upper and lower gastrointestinal tract were corre-
lated not only with established risk factors (tumor size,
mitotic rate and proliferative activity), but also with cyto-
logical subtype, tumor site, occurrence of metastasis and
overall survival. Thus, site-independent risk assessment
according to Fletcher [10] and site-dependent criteria of
malignancy according to Miettinen were considered
[11,31] since these criteria are being used to decide on
(neo-) adjuvant therapy.
Methods
Surgical specimens and histology
The pathology departments at the universities of Brussels
(Belgium), Varese (Italy) and Kiel (Germany) provided a
host of primary gastrointestinal mesenchymal tumors that
had been formalin-fixed, paraffin embedded and col-
lected during the period 1973–2001 [32]. None of the
tumors was treated with imatinib. The retrospective study
was undertaken in accordance with institutional guide-
lines. Informed consent for scientific evaluation had been
obtained from patients at their primary clinical treatment.
Serial sections were made from the tissues mentioned
above and stained with hematoxilin and eosin, then sub-
ject to a KIT immunoassay to identify GIST cases. We
detected 104 KIT-positive tumors, 10 of which came from
Brussels, 46 from Varese, and 48 from Kiel. The collective
consisted of 59 female and 45 male patients; their ages
ranged from 24 to 90 years (mean 62). The tumors had
been resected from the upper and lower gastrointestinal
tract (stomach 60, small intestine 37 and large intestine
7). The GIST sizes ranged from 0.4 cm to 30 cm in diam-
eter (mean 5.5 cm); 42% were smaller than 5 cm (12% <
2 cm) and 58% ≥ 5 cm (21% < 10 cm).
Follow-up information was available on 49 patients. Dur-
ing a period of up to 284 months (mean 75), 33 patients
survived disease free. Further 6 patients were still alive at
the end of the follow-up, but sustained metastases in liver,
omentum and/or peritoneum (5) or a local recurrence
(1). Ten patients died of the disease, all of them had
metastases. (Follow-up was not available for 5 patients
who had metastases at the time of primary diagnosis.)
The tumor sections were reviewed and classified as epithe-
lioid or spindle cell type according to the dominant pat-
tern. Nest-like, trabecular and pleomorphic
differentiation was taken as a predominantly epithelioid
subtype [9]. Nuclear atypia was graded as being absent,
mild or severe. The risk of malignancy was classified
according to Fletcher's [10] and Miettinen's [11] criteria.BMC Cancer 2008, 8:204 http://www.biomedcentral.com/1471-2407/8/204
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Immunohistochemistry
Staining reactions for KIT, CD34, Ki67 antigen, P53, BCL-
2 and Cyclin D1 were performed using commercially
available antibodies (Table 1). Prior to immunostaining
with the specific antibodies, the slides were pretreated
with citric acid in a pressure cooker for antigen retrieval.
Endogenous peroxidase was inactivated with H2O2 block-
ing reagent (DAKO Cytomation, Hamburg, Germany) for
20 min. Slides were incubated with the primary antibod-
ies at room temperature for 30 min, then immunostained
using the avidin-biotin complex peroxidase method (ABC
Elite Kit, Vector Laboratories, Burlingham, CA). Com-
plexes were visualized with diaminobenzidine (DAB sub-
strate kit, Vector Laboratories).
Without knowledge of the clinical data, UP and NSG eval-
uated independently all tumor specimens by light micro-
scopy. Most of the judgments agreed; doubtful cases were
scrutinized once more or discarded.
Control tissues were added to every staining patch. The
immunostaining of P53 was controlled particularly upon
decorated nuclei in the mucous membrane, whereas nor-
mal stromal tissue, which does not proliferate, remained
unstained (negative control). Therefore all GISTs, in
which cells showed an intensive nuclear reactivity for P53,
were considered positive. This 0% cut-off decision was
further supported by the fact that the mutated P53 has a
longer half-life than the wild type protein [33]. Also for
Cyclin D1, all positive nuclear reactions were counted;
however, staining artefacts reduced this sample to 80 spec-
imens.
For KIT, CD34 and BCL-2, clear cytoplasmic labels were
considered positive. Ki67 indicates proliferative activity
during the entire cell cycle, except for the G0 phase. The
percentage of Ki67 positive nuclei was reported from
1,000 tumor cells within representative areas.
Statistical analysis
The correlation between P53, BCL-2 and Cyclin D1
expression as well as tumor size, mitotic rate, proliferative
activity, nuclear atypia, occurrence of metastasis, tumor
differentiation, tumor site and Fletcher's risk criteria was
analyzed by means of the Pearson chi-square test and
Fisher's exact test. The software package SPSS 13.0 for
Windows (SPSS Inc, Chicago, IL) was used for these calcu-
lations. Statistical significance was assumed at p < 0.05.
Overall survival was evaluated according to Kaplan-Meier
(not shown).
Results
The histological record yielded spindle cell differentiation
with whorl-like or palisading patterns in 67 GISTs (64%).
Pure or predominantly epithelioid differentiation with
polygonal tumor cells containing clear cytoplasm was
found in 37 GISTs (36%). The mitotic rate ranged from
0–125 nuclear divisions (mean 3.5; median 11) when
counted for each patient within 50 microscopic high
power fields (HPF). In detail, the mitotic rates were less
than 5/50 HPF in 53 GISTs, 5–10/50 HPF (n = 15), and
more than 10/50 HPF (n = 36). Nuclear atypia was mild
in 39 cases and severe in 38, but 27 GISTs did not show
any. According to Fletcher's criteria, the risk of malignancy
appeared very low in 12 GISTs, low in 26, intermediate in
18 and high in 48 cases.
Metastases had developed only in GISTs with intermedi-
ate (3/3) or high (17/27) risk of malignancy (p = 0.001).
Patients with metastases had a significantly poorer out-
come than those without (p = 0.011). The proliferative
activity, detected upon Ki67, ranged from 0–46%
(median 7%). A threshold of 7% was applied for statisti-
cal analysis. Thus, minor proliferative activity allocated in
67 of 104 cases, while it was ≥ 7% in 37 GISTs.
Scattered, but strong nuclear P53 decoration characterized
38% of the tumors (40/104) (Fig. 1). The expression of
P53 was significantly correlated with high mitotic rate (p
= 0.013), high proliferative activity (p = 0.01), severe
nuclear atypia (p = 0.02) and with the epithelioid subtype
(p = 0.002). P53 was significantly correlated with
Fletcher's criteria (p < 0.0001). P53 expression was
detected most often in GISTs originating in the colon
(71%), followed by GISTs deriving from the small intes-
tine (46%) and stomach (32%); these observations, how-
ever, were statistically not significant (for details see
Tables 2 and 3).
Table 1: List of primary antibodies
Antigen Antibody Dilution Source
BCL-2 124 1:100 DAKO Cytomation, Glostrup, Denmark
CD34 QBEND 10 1:1500 Immunotech, Marseille, France
Cyclin D1 P2D11F11 1:10 Novocastra Laboratories Ltd, Newcastle, UK
Ki67 Ki-S5 1:1000 Dept. Hematopathology, University of Kiel, Germany
KIT K1906 1:30 DAKO Cytomation, Glostrup, Denmark
P53 DO-1 1:20 Calbiochem (Merck, Darmstadt, Germany)BMC Cancer 2008, 8:204 http://www.biomedcentral.com/1471-2407/8/204
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With regard to epithelioid differentiation, 22 GISTs were
P53 positive, of which 12 were localized in the stomach
and 10 in the intestine.
Primary resections from GISTs with metastases showed
P53 label more often than those without (65% vs. 39%).
Survival analysis showed P53 positive tumors in 70% (7/
10) of the patients who died, but only in 18% (7/39) sur-
vivals. The outcome of patients with P53 positive GISTs
tended to be poorer than in negative cases, but these data
were not significant.
There was neither a correlation between P53 and BCL-2
expression nor between P53 and Cyclin D1 expression.
Diffuse cytoplasmic BCL-2 staining was found in 69%
(72/104) of the GISTs; it was of moderate intensity in 26
cases and of strong intensity in 54 cases (Fig. 2). This
staining pattern was very similar to that of CD34, which
was found in 73% (76/104) of the GISTs. Almost half of
the tumors (48%) coexpressed BCL-2 and CD34 (p =
0.002). All CD34 negative GISTs were positive for BCL-2,
and all BCL-2 negatives were positive for CD34. No GIST
was negative for both, CD34 and BCL-2. We observed
BCL-2 predominantly in GISTs of the small intestine
(86%), whereas CD34 labeled significantly gastric GISTs
(91%; p = 0.001). The correlation between BCL-2 expres-
sion, tumor size and mitotic rate was not significant
(Tables 2 and 3).
Nuclear Cyclin D1 expression was found in 48% (38/80)
of the GISTs (Fig. 3). In 18 of them, more than 30% of the
tumor cells were labeled. According to our statistical anal-
yses, Cyclin D1 expression was unrelated to all prognostic
parameters as well as to histological subtype and tumor
site (Tables 2 and 3). Interestingly, Cyclin D1 expression
Table 2: P53, BCL-2 and Cyclin D1 expression in GISTs related to clinicopathological features
Tumor size (cm) Mitotic rate/50 HPF Malignancy risk F Malignancy risk M
<2 2–5 5–10 >10 <5 5–10 >10 very 
low




P53 2/10 7/31 22/37 9/22 13/50 7/15 20/35 1/10 3/25 10/18 26/47 3/24 5/17 32/59
20% 23% 37% 41% 26% 47% 57% 10% 12% 56% 55% 13% 29% 54%
BCL2 5/9 22/30 30/37 15/22 34/48 9/15 29/35 4/8 18/25 15/18 35/47 13/22 14/17 45/59
56% 73% 81% 68% 71% 60% 83% 50% 72% 83% 74% 59% 82% 76%
CyD1 3/7 12/26 15/29 4/18 19/40 5/12 10/28 2/5 10/21 8/16 14/38 6/18 8/15 20/47
43% 46% 52% 22% 48% 42% 36% 40% 47% 50% 37% 33% 53% 42%





absent mild severe <7% ≥ 7% spindle 
cell




P53 6/26 13/37 21/37 14/60 22/40 18/63 22/37 19/58 16/35 5/7
23% 35% 56% 23% 55% 29% 59% 33% 46% 71%
BCL2 18/25 25/36 29/37 9/26 27/72 43/61 29/37 37/56 30/35 5/7
72% 69% 78% 35% 38% 70% 78% 66% 86% 71%
CyD1 9/18 9/28 16/34 21/46 12/34 21/48 13/32 17/45 15/30 2/5
50% 32% 47% 46% 35% 44% 41% 38% 50% 40%
CyD1: Cyclin D1, Figures 2/10 describe 2 out of 10 cases, bold: statistical significance, HPF: microscopic high power fields, F: Fletcher [10], M 
Miettinen [11], prob malign: probably malignant
Nuclear P53 expression in a metastasized duodenal GIST, 8  cm in diameter, showing spindle cell differentiation Figure 1
Nuclear P53 expression in a metastasized duodenal GIST, 8 
cm in diameter, showing spindle cell differentiation.BMC Cancer 2008, 8:204 http://www.biomedcentral.com/1471-2407/8/204
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was detected in only 19% (3/16) of the GISTs with metas-
tases (stomach 1, duodenum 2), but in 62% (8/13) of
GISTs without metastases from various tumor sites (stom-
ach 3, duodenum 3, ileum 1, colon 1).
Discussion
Activating mutations of the genes c-kit and PDGFRα char-
acterize the tumor entity GIST. The mutation status is
important for prognosis and a predictive factor for the
response to therapy with the tyrosine kinase receptor
inhibitor imatinib (Glivec ®) [3,12,34-37]. The risk of
malignancy is correlated with tumor size, proliferative
activity and DNA ploidy (in preparation) [38,39]. It is
conceivable that alterations in the genes involved in cell
cycle control may modulate the biological behavior of
GIST [15].
We tested a number of gene products on GISTs and found
that P53 correlated significantly with large tumor size,
high mitotic rate, proliferative activity, Fletcher's and
Miettinen's high risk criteria, severe nuclear atypia and
with epithelioid differentiation. However, BCL-2 and Cyc-
lin D1 labels did not correlate with the said clinicopatho-
logical parameters.
Our data, showing P53 expression significantly associated
with established prognostic criteria, were in agreement
with most previous GIST studies [16,18,40,41]. P53
expression appeared more often in metastasized GISTs
than in tumors with disease-free follow-up. These data
indicate the impact of the tumor suppressor gene p53 on
GIST progression. To our surprise, P53 expression was sig-
nificantly associated with predominantly epithelioid
tumor differentiation, independently of tumor site. In
general, gastric GISTs with epithelioid differentiation are
characterized by PDGFRα mutations and good prognosis.
But high risk has been reported upon epithelioid and
mixed cell type GISTs without mutated genes PDGFRa
and c-kit [42]. Such tumors develop at different sites. Since
epithelioid GISTs have been described with pleomorphic
patterns [9], we suggest that our P53 immunoassay
detected the epithelioid subtype with variable differentia-
tion in stomach and intestine.
Previous studies have claimed BCL-2 being of diagnostic
and prognostic relevance [17,19,21]. Other groups did
not attribute prognostic value to BCL-2 [20,29,40]. Our
results did not recommend BCL-2 for diagnosis, because
it was expressed only in 73% of the GISTs. Otherwise, this
percentage does not aid risk assessment, because it was
not significant.
Nuclear Cyclin D1 immunoreactivity in a metastasized gastric  GIST, 6 cm in diameter, showing mixed epithelioid-spindle  cell differentiation Figure 3
Nuclear Cyclin D1 immunoreactivity in a metastasized gastric 
GIST, 6 cm in diameter, showing mixed epithelioid-spindle 
cell differentiation.
Table 3: Correlation of P53, BCL-2 and Cyclin D1 expression in 
KIT positive GISTs with clinicopathological features
P53 BCL-2 Cyclin D1
Tumor size 0.01 0.408 0.243
Mitotic rate 0.013 0.207 0.625
Risk of malignancy (Fletcher [10]) <0.0001 0.36 0.776
Risk of malignancy (Miettinen [11]) 0.001 0.196 0.512
Nuclear atypia 0.02 0.676 0.38
Proliferative activity (Ki67) 0.01 0.794 0.352
Histological subtype 0.002 0.391 0.782
Tumor site 0.099 0.118 0.573
Bold: significant probability
Strong cytoplasmic BCL-2 expression in a GIST from the  large intestine showing spindle cell differentiation Figure 2
Strong cytoplasmic BCL-2 expression in a GIST from the 
large intestine showing spindle cell differentiation.BMC Cancer 2008, 8:204 http://www.biomedcentral.com/1471-2407/8/204
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However, BCL-2 label was predominantly observed in
intestinal GISTs and CD34 expression in gastric GISTs
[32]. These findings suggest that GISTs may develop from
different somatic subtypes of stem cells, depending on
their localization. This hypothesis has received support
from two studies showing PDGFRα mutations to occur in
gastric GISTs and epithelioid differentiation [42,43].
Haller et al. [44] postulated different regulatory mecha-
nisms for the downstream signaling pathway in GISTs
with c-kit and PDGFRα mutations, respectively. Steinert
and colleagues [23] found BCL-2 expression frequently
associated with progression-free survival of GIST patients
who had been treated with imatinib. The authors specu-
lated that the KIT signaling pathway drives GIST develop-
ment and may induce BCL-2 expression.
Tumors, e.g. mantle cell lymphomas, in which cyclin D1 is
involved as an oncogene, overexpression or aberrant
expression has been supposed to correlate with poor prog-
nosis [45]. In contrast, the outcome was worse for patients
when Cyclin D1 expression was low in their GISTs [29].
We found reduced Cyclin D1 expression in GISTs with
metastases. However, the survival records were too sparse
for statistic analysis. Finally, Cyclin D1 expression did not
correlate with the important prognostic indicators like
tumor size and mitotic rate. We are therefore unable to
confirm that reduced levels of Cyclin D1 represent an une-
quivocal prognostic factor in GISTs.
Conclusion
Our investigation confirmed P53 being a powerful immu-
nohistochemical marker for predicting the risk of malig-
nancy in GISTs. Alterations in this tumor suppressor gene
seemingly increase the risk of malignancy during tumor
progression. In addition, we found P53 significantly cor-
related with predominantly epithelioid differentiation,
independent of tumor site. The antiapoptotic protein
BCL-2 and the cell cycle regulator Cyclin D1, however,
appeared not helpful in GIST diagnosis and prognosis.
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